Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma

Blood Adv. 2020 Sep 8;4(17):4086-4090. doi: 10.1182/bloodadvances.2020002060.

Hamza Hashmi¹, Abu-Sayeef Mirza², Alicia Darwin³, Constantine Logothetis², Franco Garcia², Anuhya Kommalapati⁴, Rahul S Mhaskar⁵, Christina Bachmeier¹, Julio C Chavez^{4

6}, Bijal Shah^{4

6}, Javier Pinilla-Ibarz^{4

6}, Farhad Khimani^{1

6}, Aleksandr Lazaryan^{1

6}, Hien Liu^{1

6}, Marco L Davila^{1

6}, Frederick L Locke^{1

6}, Taiga Nishihori^{1

6}, Michael D Jain^{1

6}

¹ Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
² Department of Internal Medicine and.
³ Morsani College of Medicine, University of South Florida, Tampa, FL.
⁴ Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and.
⁵ Office of Research, Innovation & Scholarly Endeavors (RISE) and.
⁶ Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL.

Abstract

VTE developed in 11% of lymphoma patients after CAR T-cell therapy and was managed safely with anticoagulation.
Coagulation abnormalities after CAR T-cell therapy occur but do not commonly lead to bleeding events.